Get Cash Back and $0 Commissions
+ The Power of TradeStation

Frank Magliochetti - Discusses 3D Bioprinters and Functional Human Skin for Transplants

[End Subhead]
[Start Distributor]
Accesswire 6-Sep-2017 12:50 AM
[End Distributor]
LAWRENCE, MA / ACCESSWIRE / September 6, 2017 /In the age of modern technology breakthroughs are happening in every industry, yet few of those impact the quality of life as much as in the field of healthcare. Frank Magliochetti, managing partner of Parcae Capital Corporation, talks about an invention that shatters the barriers of publicly accessible medical transplantation. In December 2016, a study conducted by a team of Spanish scientists from the Universidad Carlos III de Madrid revealed the development of a 3D bioprinter that can automaticallygenerate bioengineered human skin suitable for both medical transplantation and laboratory testing of pharmaceuticals, cosmetics and chemical products. The new technology has already been successfully applied in the Hospital General Universitario Gregorio Maran in treatment of severe burns and other skin conditions.
"This method of bioprinting allows skin to be generated in a standardized, automated way, and the process is less expensive than manual production."Says Alfredo Bisac, CEO of BioDan group, Spanish bioengineering company that is commercializing the new technology. This bioskin is among the first living human organs to enter the marketplace, following the 3D bioprinted human ear, bone and muscle developed by a team of scientists from the Wake Forest Baptist Medical Center. Instead of colored ink commonly associated with printing as we know it, the bioprinter uses biological components taken from each individual's cells and positions them in precise locations on the print bed with the help of faucets. The whole process is controlled by a computer to maximize precision, mixing accuracy and dosage of each component. As a result, the bioprinter identically replicates the two layers of human skin, the outer epidermis (external, protective layer composed of keratin cells) and the inner, deeper dermis (consisting of fibroblasts that generate collagen, which is responsible for the elasticity and mechanical strength of the skin).
As an expert, Frank Magliochetti specifically points to two essential advantages of the new technology timely delivery and the usage of only human cells. Spanish scientists have already been manually producing bioengineered skin, yet it took three weeks to produce the amount of skin necessary to treat a large wound. The automated process of 3D bioprinting allows to generate 100x100 centimeters of bioskin in mere 35 minutes. "We use only human cells and components to produce skin that is bioactive and can generate its own human collagen, thereby avoiding the use of the animal collagen that is found in other methods."Notes Alfredo Bisac. The Spanish team of scientists is currently involved in the research of generating other human organs with the help of the new technology.
An outstanding veteran of medical, pharmaceutical and financial industries, Frank Magliochetti has obtained his master's degree in Pharmacology and Toxicology from Northeastern University. Throughout his career, Frank has held leading positions at Sandoz, Chartwell Diversified Services, Haemonetics and Kontron Medical. Currently Magliochetti is the CEO of Sympta Corporation, a provider of allergy testing and treatment services for existing medical practices, Chairman of Rehab Medical Holdings, orthopedic medical device holding company, and the founder and managing partner of Parcae Capital, a consulting company that assists healthcare, media and alternative energy industries with building, restructuring and transforming their business.
Frank Magliochetti - Founder and Managing Partner of Parcae Capital:
Frank Magliochetti - Highlights the Potential of Wearable Sensors in Healthcare Diagnosis:
Frank Magliochetti - Proud to Lead New Parcae Capital Project - Just Fellowship:
Contact Information:
SOURCE: Frank Magliochetti